Walvax Biotechnology has announced it will terminate its plan for a Hong Kong initial public offering, Caixin reported, with the company citing market conditions and business development plans.
The Kunming-based company also said it would expand its pneumonia vaccine production capacity with an investment of 695 million yuan ($109.2 million).
Read the full report: Caixin.
SEE MORE:
Beijing Biotech Firm Banks on GM Corn in Bid to be China’s Monsanto
Covid Jab Maker Clover Raises $240m in IPO
Hong Kong biotech could thrive in Covid crisis